Compare LINK & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINK | ACET |
|---|---|---|
| Founded | 1984 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 83.3M |
| IPO Year | 2007 | 2017 |
| Metric | LINK | ACET |
|---|---|---|
| Price | $4.31 | $4.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | N/A | ★ $34.83 |
| AVG Volume (30 Days) | 45.1K | ★ 297.1K |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,890,000.00 | N/A |
| Revenue This Year | $40.45 | N/A |
| Revenue Next Year | $19.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $2.66 | $0.46 |
| 52 Week High | $10.34 | $9.97 |
| Indicator | LINK | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 30.01 | 25.48 |
| Support Level | $3.91 | N/A |
| Resistance Level | $5.10 | $8.62 |
| Average True Range (ATR) | 0.39 | 0.61 |
| MACD | -0.16 | -0.20 |
| Stochastic Oscillator | 3.96 | 1.91 |
Interlink Electronics Inc is a provider of sensing technologies and printed electronics solutions that enable Human-Machine Interface (HMI) devices and Internet-of-Things (IoT) applications. Its broad product and technology portfolio spans force and touch sensors, piezoelectric sensors, rugged HMI sensors, wearable and textile-based sensors and electrochemical gas and environmental sensors, along with instruments and fully integrated systems based on its sensor technologies. It serves blue-chip customers and emerging companies across diverse end-use markets, including medical, industrial, automotive, consumer electronics, wearables, environmental monitoring, and specialty applications. It operates in single segment: the design, development, and manufacture of sensor technologies.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).